The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3433716)

Published in Clin Dev Immunol on August 27, 2012

Authors

F Bellanti1, G Vendemiale, E Altomare, G Serviddio

Author Affiliations

1: Department of Medical and Occupational Sciences, C.U.R.E. Centre for Liver Disease Research and Treatment, University of Foggia, Italy.

Articles cited by this

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47

Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93

Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03

Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87

IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol (2002) 11.22

Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med (2004) 8.12

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86

Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect (2011) 6.48

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 6.16

Lambda interferon inhibits hepatitis B and C virus replication. J Virol (2005) 5.47

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 4.21

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57

Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 3.46

Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol (2004) 3.25

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther (2011) 3.10

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology (2010) 3.00

Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol (2008) 2.98

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol (2011) 2.84

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology (2010) 2.78

Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42

Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun (2008) 2.40

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology (2010) 2.02

IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology (2012) 1.96

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut (2010) 1.85

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol (2010) 1.82

Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 1.81

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69

IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64

Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 1.60

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology (2010) 1.59

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis (2010) 1.58

New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut (2012) 1.50

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology (2010) 1.47

IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol (2011) 1.43

Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology (2012) 1.43

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology (2011) 1.43

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One (2011) 1.39

Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One (2011) 1.38

IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology (2011) 1.30

Interferon lambdas: the next cytokine storm. Gut (2011) 1.25

Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A (2011) 1.19

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol (2010) 1.19

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One (2010) 1.17

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus. Eur J Gastroenterol Hepatol (2011) 1.12

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther (2012) 1.11

Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother (2012) 1.08

Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06

Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol (2011) 1.05

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients. PLoS One (2012) 1.05

Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04

A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology (2011) 1.03

Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res (2010) 1.02

The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. Dig Dis Sci (2012) 1.01

Interferon-λ in HCV Infection and Therapy. Viruses (2010) 0.98

Review article: chronic hepatitis C--natural history and cofactors. Aliment Pharmacol Ther (2005) 0.96

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis (2011) 0.94

Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One (2012) 0.94

IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology (2006) 0.92

Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother (2011) 0.89

Id2 leaves the chromatin of the E2F4-p130-controlled c-myc promoter during hepatocyte priming for liver regeneration. Biochem J (2006) 0.89

IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res (2010) 0.88

Do lambda-IFNs IL28A and IL28B act on human natural killer cells? Proc Natl Acad Sci U S A (2011) 0.88

IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J Infect Dis (2011) 0.87

Antiviral strategies: the present and beyond. Curr Mol Pharmacol (2009) 0.86

The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest (2010) 0.86

Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant (2012) 0.83

Hepatitis C virus kinetics in chimeric mice during antiviral therapy. Hepatology (2007) 0.83

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse. AIDS (2011) 0.83

IL28B CC genotype is associated with higher all-cause mortality in antiretroviral-treated HIV-infected patients. AIDS Res Hum Retroviruses (2012) 0.82

Current and future treatment of hepatitis C. Indian J Gastroenterol (2001) 0.82

Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals. AIDS (2012) 0.82

Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol Cell Biochem (2011) 0.80

Genetic variations in IL28B and allergic disease in children. PLoS One (2012) 0.80

Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin. Int J Antimicrob Agents (2011) 0.79

Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes. Hepatology (2012) 0.77

Articles by these authors

Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury. Gut (2008) 1.84

Protein oxidation and lens opacity in humans. Invest Ophthalmol Vis Sci (2000) 1.29

Effects of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease. Scand J Gastroenterol (1989) 1.27

An update on the role of free radicals and antioxidant defense in human disease. Int J Clin Lab Res (1999) 1.14

Role of lipid peroxidation in the pathogenesis of myopic and senile cataract. Br J Ophthalmol (1996) 1.13

Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology (2001) 1.07

Gallbladder motility and cholesterol crystallization in bile from patients with pigment and cholesterol gallstones. Eur J Clin Invest (2000) 1.07

Acute ethanol administration induces oxidative changes in rat pancreatic tissue. Gut (1996) 1.02

Oxidative retinal products and ocular damages in diabetic patients. Free Radic Biol Med (1998) 0.99

Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J Nutr (2000) 0.98

Increased oxidative stress in dimethylnitrosamine-induced liver fibrosis in the rat: effect of N-acetylcysteine and interferon-alpha. Toxicol Appl Pharmacol (2001) 0.98

Effect of acetaminophen administration on hepatic glutathione compartmentation and mitochondrial energy metabolism in the rat. Biochem Pharmacol (1996) 0.98

Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res (2010) 0.97

Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model. Eur J Clin Invest (2008) 0.97

Oxidative stress in symptom-free HCV carriers: relation with ALT flare-up. Eur J Clin Invest (2001) 0.96

Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumour progression. Gut (2002) 0.94

Bioavailability of a new effervescent tablet of ibuprofen in healthy volunteers. Eur J Clin Pharmacol (1997) 0.94

Data available on the extent of cocaine use and dependence: biochemistry, pharmacologic effects and global burden of disease of cocaine abusers. Curr Med Chem (2012) 0.93

Mitochondrial oxidative damage and myocardial fibrosis in rats chronically intoxicated with moderate doses of ethanol. Toxicol Lett (2001) 0.92

Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem (2010) 0.91

Increased lipid peroxidation in type 2 poorly controlled diabetic patients. Diabete Metab (1993) 0.91

Mitochondrial oxidative alterations following partial hepatectomy. Free Radic Biol Med (1999) 0.91

Hepatic glutathione content in patients with alcoholic and non alcoholic liver diseases. Life Sci (1988) 0.90

Modulation of endometrial redox balance during the menstrual cycle: relation with sex hormones. J Clin Endocrinol Metab (2002) 0.89

Reperfusion injury of the liver: role of mitochondria and protection by glutathione ester. J Surg Res (1999) 0.89

Decreased hepatic glutathione in chronic alcoholic patients. J Hepatol (1986) 0.88

A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B. Hepatology (1996) 0.88

Increased generation of reactive oxygen species in isolated rat fatty liver during postischemic reoxygenation. Transplantation (2001) 0.87

The effect of acute oral erythromycin on gallbladder motility and on upper gastrointestinal symptoms in gastrectomized patients with and without gallstones: a randomized, placebo-controlled ultrasonographic study. Am J Gastroenterol (2000) 0.86

Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol (2009) 0.86

Depression of biliary glutathione excretion by chronic ethanol feeding in the rat. Life Sci (1984) 0.85

T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. Clin Exp Immunol (2013) 0.84

Dietary fatty acids, age-related cognitive decline, and mild cognitive impairment. J Nutr Health Aging (2008) 0.84

Human diabetic cataract: role of lipid peroxidation. Diabete Metab (1995) 0.84

Sonographic evaluation of gallstone burden in humans. Ital J Gastroenterol (1994) 0.84

Food deprivation exacerbates mitochondrial oxidative stress in rat liver exposed to ischemia-reperfusion injury. J Nutr (2001) 0.83

Mitochondrial oxidative phosphorylation and intracellular glutathione compartmentation during rat liver regeneration. Hepatology (1995) 0.83

Vascular risk factors, alcohol intake, and cognitive decline. J Nutr Health Aging (2008) 0.82

Computed-tomographic-guided biopsy of thoracic nodules: a revision of 583 lesions. Clin Ter (2008) 0.82

Ethanol-induced changes of intracellular thiol compartmentation and protein redox status in the rat liver: effect of tauroursodeoxycholate. J Hepatol (1998) 0.82

Oxidation of circulating proteins in alcoholics: role of acetaldehyde and xanthine oxidase. J Hepatol (1996) 0.81

Prolonged remission of neuro-Behcet disease following autologous transplantation. Int J Immunopathol Pharmacol (2007) 0.81

Immunoglobulin secretion by peripheral blood and bone marrow B cells in patients with multiple myeloma. Studies by the reverse haemolytic plaque assay. Clin Exp Immunol (1984) 0.81

Bioenergetics in aging: mitochondrial proton leak in aging rat liver, kidney and heart. Redox Rep (2007) 0.80

Haemodynamic effects of propranolol, octreotide and their combination during fasting and post-prandial splanchnic hyperaemia in patients with cirrhosis. Eur J Gastroenterol Hepatol (2001) 0.79

Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. Dig Liver Dis (2005) 0.79

Increased plasma levels of glutathione and malondialdehyde after acute ethanol ingestion in humans. J Hepatol (1989) 0.79

Alteration of mitochondrial F0F1 ATP synthase during aging. Possible involvement of oxygen free radicals. Ann N Y Acad Sci (1996) 0.79

Interaction of ethanol with acetaminophen metabolism in the baboon. Biochem Pharmacol (1984) 0.78

Feasibility and safety of granulocytapheresis in Crohn's disease: a prospective cohort study. Gastroenterol Clin Biol (2010) 0.78

Oxidative modification of proteins in chronic alcoholics. Boll Soc Ital Biol Sper (1996) 0.78

Interaction of acute ethanol administration with acetaminophen metabolism and toxicity in rats fed alcohol chronically. Alcohol Clin Exp Res (1984) 0.78

Kinetics of fast haemoglobin in diabetic rats. Diabetologia (1982) 0.78

[Glutathione in the treatment of chronic fatty liver diseases]. Recenti Prog Med (1995) 0.78

Effect of acute and chronic cimetidine administration on acetaminophen metabolism in humans. Am J Gastroenterol (1987) 0.77

Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease. Free Radic Res (2013) 0.77

Circadian variations of cortisol, melatonin and lymphocyte subpopulations in geriatric age. Int J Immunopathol Pharmacol (2010) 0.77

Effect of Propofol, Sevoflurane and Desflurane on systemic redox balance. Int J Immunopathol Pharmacol (2007) 0.77

A multicenter double-blind controlled trial comparing lidamidine HCl and loperamide in the symptomatic treatment of acute diarrhoea. Arzneimittelforschung (1986) 0.77

Chronic ethanol intake induces oxidative alterations in rat testis. J Appl Toxicol (1997) 0.77

Chronic ethanol administration induces oxidative alterations and functional impairment of pancreatic mitochondria in the rat. Digestion (2000) 0.77

Evidence of lower oxidative stress in the air spaces of patients with reversible COPD. Int J Immunopathol Pharmacol (2006) 0.77

Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results. Arzneimittelforschung (1992) 0.76

Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. Eur J Clin Invest (2003) 0.76

Age related changes of the mitochondrial energy metabolism in rat liver and heart. Arch Gerontol Geriatr (1994) 0.76

Change of γδTCR-expressing T cells in healthy aging. Int J Immunopathol Pharmacol (2011) 0.76

Arterial endothelial dysfunction and idiopathic deep venous thrombosis. J Biol Regul Homeost Agents (2012) 0.76

Acute and chronic effects of ethanol on biliary secretion of bilirubin and bile acids. Subst Alcohol Actions Misuse (1986) 0.76

Does acute ethanol really protect against acetaminophen hepatotoxicity? Am J Gastroenterol (1986) 0.75

Altered biliary excretion of acetaminophen in rats fed ethanol chronically. Drug Metab Dispos (1984) 0.75